复星医药注射用HLX43获美国FDA药品临床试验批准

Core Viewpoint - Fosun Pharma's subsidiary, Shanghai Fuhong Hanlin Biotechnology Co., has received FDA approval to initiate Phase I clinical trials for HLX43, a targeted PD-L1 antibody-drug conjugate for thymic carcinoma treatment [1] Group 1: Company Developments - The new drug HLX43 is a conjugate of a novel DNA topoisomerase I inhibitor small molecule toxin-peptide linker and a self-developed PD-L1 targeting antibody [1] - The clinical trials will be conducted globally in locations including Australia, Japan, and the United States once conditions are met [1] Group 2: Industry Context - The targeted PD-L1 antibody-drug conjugate (ADC) is aimed at treating advanced/metastatic solid tumors [1]